Lund, Sweden, August 30 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today that it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 4-6, 2018 at the St. Regis New York Hotel in New York City.
CEO Per Norlén will provide an overview of the Company's business during the live presentation, and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
Event: Company presentation at the 20th Annual Rodman & Renshaw Global Investment Conference
Date: September 6, 2018
Time: 3:25-3:50 pm EDT (9:25-9:50 pm CEST)
Location: Library (2nd floor); the St. Regis New York Hotel in New York City
The presentation will be webcast live. To access the webcast, please use the direct link http://wsw.com/webcast/rrshq28/atorx/ or visit www.rodmanevents.com. The webcast replay will remain available for 90 days following the live presentation.
For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 286 44 95
The information was submitted for publication, through the agency of the contact person set out above, at 2:00 p.m. CEST on August 30, 2018.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes four lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527).
ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. For more information, please visit www.alligatorbioscience.com.